Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,281 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Maeda H, et al. Among authors: hori k. J Control Release. 2000 Mar 1;65(1-2):271-84. doi: 10.1016/s0168-3659(99)00248-5. J Control Release. 2000. PMID: 10699287 Review.
Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism.
Hori K. Hori K. Cancer Metastasis Rev. 2012 Jun;31(1-2):109-22. doi: 10.1007/s10555-011-9333-9. Cancer Metastasis Rev. 2012. PMID: 22101805 Review.
The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors.
Hori K, Nishihara M, Shiraishi K, Yokoyama M. Hori K, et al. J Pharm Sci. 2010 Jun;99(6):2914-25. doi: 10.1002/jps.22038. J Pharm Sci. 2010. PMID: 20039393
Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: macromolecular delivery according to tumor vascular growth stage.
Hori K, Nishihara M, Yokoyama M. Hori K, et al. J Pharm Sci. 2010 Jan;99(1):549-62. doi: 10.1002/jps.21848. J Pharm Sci. 2010. PMID: 19544373
Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth.
Hori K, Furumoto S, Kubota K. Hori K, et al. Cancer Sci. 2008 Jul;99(7):1485-91. doi: 10.1111/j.1349-7006.2008.00834.x. Epub 2008 Apr 29. Cancer Sci. 2008. PMID: 18452559
Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
Hori K. Hori K. Chemotherapy. 2005 Oct;51(6):357-60. doi: 10.1159/000088961. Epub 2005 Oct 14. Chemotherapy. 2005. PMID: 16227690 Review.
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
Hori K, Saito S, Kubota K. Hori K, et al. Br J Cancer. 2002 May 20;86(10):1604-14. doi: 10.1038/sj.bjc.6600296. Br J Cancer. 2002. PMID: 12085211 Free PMC article.
Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).
Hori K, Saito S. Hori K, et al. Br J Cancer. 2004 Jan 26;90(2):549-53. doi: 10.1038/sj.bjc.6601582. Br J Cancer. 2004. PMID: 14735207 Free PMC article.
Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
Hori K, Saito S, Sato Y, Kubota K. Hori K, et al. Med Sci Monit. 2001 Jan-Feb;7(1):26-33. Med Sci Monit. 2001. PMID: 11208488
Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Hori K, et al. Jpn J Cancer Res. 1999 Sep;90(9):1026-38. doi: 10.1111/j.1349-7006.1999.tb00851.x. Jpn J Cancer Res. 1999. PMID: 10551334 Free PMC article.
1,281 results
Jump to page
Feedback